Zhu Qinghua, Huang Qingqing, He Xiaohua, Jiang Miaomiao, Fu Junkai, Ding Chenyuan
Department of Respiratory Medicine, Yiwu Central Hospital, Jinhua, China.
Department of Dermatology, Yiwu Central Hospital, Jinhua, China.
Int Arch Allergy Immunol. 2025 Jul 28:1-19. doi: 10.1159/000547102.
Lung adenocarcinoma (LUAD) is a common and fatal form of lung cancer, with varying expressions of midkine (MDK) and tissue inhibitor of metalloproteinase (TIMP1) across different cancers. However, their specific roles in LUAD progression and tumor immunity remain unclear.
We analyzed RNA-seq data from TCGA using the ggpubr R package to compare MDK and TIMP1 expression in normal versus LUAD tissues. This was validated through qRT-PCR and Western blot. LUAD patients were categorized into high and low expression groups for MDK and TIMP1, and their impacts on overall survival (OS), disease-free interval (DFI), progression-free interval (PFI), and disease-specific survival (DSS) were assessed using Kaplan-Meier curves and receiver operation characteristic curves. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analyses were performed for 50 genes similar to MDK and TIMP1, and a gene-gene interaction network was created with GeneMANIA, examining differentially expressed genes across both expression groups. We also evaluated the mutational landscape and immune cell infiltration correlations. Finally, the relationship between MDK, TIMP1 and immune cells was explored by immunohistochemical (IHC) experiments.
MDK and TIMP1 were significantly overexpressed in LUAD. Patients with low MDK and TIMP1 expressions had better OS, DFI, DSS, and PFI. The AUC values for MDK and TIMP1 were 0.943 and 0.875, respectively, with TIMP1 identified as a risk factor for OS. Genes similar to MDK were enriched in the Proteasome pathway, while those akin to TIMP1 were linked to endopeptidase activity. No survival impact was noted from mutations in these genes. Higher expression of MDK and TIMP1 correlated with reduced tumor purity and altered immune scores, suggesting increased immune dysfunction in the high TIMP1 group. IHC results showed that when MDK and TIMP1 expression levels were higher, B cell and TREG cell infiltration was stronger, but macrophage infiltration was weaker.
MDK and TIMP1 significantly influence the prognosis and progression of LUAD and immune cell infiltration, highlighting their potential as targets for immunotherapy.
肺腺癌(LUAD)是一种常见且致命的肺癌形式,在不同癌症中,中期因子(MDK)和金属蛋白酶组织抑制剂(TIMP1)的表达各不相同。然而,它们在LUAD进展和肿瘤免疫中的具体作用仍不清楚。
我们使用ggpubr R包分析了来自TCGA的RNA测序数据,以比较正常组织与LUAD组织中MDK和TIMP1的表达。通过qRT-PCR和蛋白质印迹法进行了验证。将LUAD患者分为MDK和TIMP1高表达组和低表达组,并使用Kaplan-Meier曲线和受试者工作特征曲线评估它们对总生存期(OS)、无病间期(DFI)、无进展间期(PFI)和疾病特异性生存期(DSS)的影响。对与MDK和TIMP1相似的50个基因进行了京都基因与基因组百科全书(KEGG)和基因本体论(GO)富集分析,并使用GeneMANIA创建了基因-基因相互作用网络,研究两个表达组中的差异表达基因。我们还评估了突变图谱和免疫细胞浸润相关性。最后,通过免疫组织化学(IHC)实验探索了MDK、TIMP1与免疫细胞之间的关系。
MDK和TIMP1在LUAD中显著过表达。MDK和TIMP1低表达的患者具有更好的OS、DFI、DSS和PFI。MDK和TIMP1的AUC值分别为0.943和0.875,TIMP1被确定为OS的危险因素。与MDK相似的基因在蛋白酶体途径中富集,而与TIMP1相似的基因与内肽酶活性有关。这些基因的突变对生存期无影响。MDK和TIMP1的高表达与肿瘤纯度降低和免疫评分改变相关,表明TIMP1高表达组免疫功能障碍增加。IHC结果显示,当MDK和TIMP1表达水平较高时,B细胞和调节性T细胞浸润较强,但巨噬细胞浸润较弱。
MDK和TIMP1显著影响LUAD的预后、进展及免疫细胞浸润,突出了它们作为免疫治疗靶点的潜力。